1351813-02-9

Basic information

• Product Name: 6-Bromo-5-nitro-1H-indazole
• Synonyms: 6-Bromo-5-nitro-1H-indazole;6-Bromo-5-nitro indazole;6-Bromo-5-nitro-1H-indazol;6-Bromo-5-nitro-2H-indazole
• CAS NO: 1351813-02-9
• Molecular Formula: C₇H₄BrN₃O₂
• Molecular Weight: 242.02956
• Mol File: 1351813-02-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 389.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.965±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.49±0.40(Predicted)
• CAS DataBase Reference: 6-Bromo-5-nitro-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-5-nitro-1H-indazole(1351813-02-9)
• EPA Substance Registry System: 6-Bromo-5-nitro-1H-indazole(1351813-02-9)

Safety Data

• Hazardous Substances Data: 1351813-02-9(Hazardous Substances Data)

Upstream product

• 39478-78-9 5-bromo-2-methylaniline 
• 1142382-25-9 5-bromo-2-methyl-4-nitroaniline 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 679839-39-5 4-bromo-2-fluoro-5-nitro-benzaldehyde 

Downstream Products

• 1351813-08-5 3-(6-(1-methyl-1H-pyrazol-4-yl)-5-nitro-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-indazol-3-yl)benzenesulfonamide 
• 1351813-09-6 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzenesulfonamide 
• 1351813-11-0 3-(5-(cyclohexylamino)-6-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzenesulfonamide 
• 1351811-41-0 C₂₃H₂₆N₆O₂S 

Relevant articles and documents

COMPOUND SERVING AS IRAK INHIBITOR

The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

COMPOUNDS

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

COMPOUNDS

Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).